ClinicalTrials.gg

Program

zorevunersen

Also written as “zorevunersen (STK-001)”, “STK-001 - Single Ascending Doses” and “STK-001 - Multiple Ascending Doses”.

Its studies are mostly in Epilepsies, Myoclonic, led by Stoke Therapeutics.

Furthest: phase 3, since Mar 6, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Stoke Therapeutics32 open or runningphase 3since Mar 6, 2025Jun 8, 2020Mar 2027phase 3 · NCT06872125

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2020First study: phase 2 study in Epilepsies, MyoclonicFirst studyNCT04442295 · 62 enrolled · United States
  2. Feb 2, 2021Phase 2 study in Epilepsies, MyoclonicNCT04740476 · 60 enrolled · United States
  3. Mar 6, 2025Phase 3 study in Epilepsies, MyoclonicNCT06872125 · 170 enrolled · United States, China, France and more

Ahead

  1. Mar 2027Primary completion: phase 3 study in Epilepsies, MyoclonicNCT06872125
  2. Mar 31, 2029Primary completion: phase 2 study in Epilepsies, MyoclonicNCT04740476

TargetBeta

SCN1A →read by rule
“Zorevunersen is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein.”study text, by rule · the study

Other programs on SCN1A

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06872125Epilepsies, Myoclonic · United States, China, France and more3Active, not recruitingMar 2027170
NCT04740476Epilepsies, Myoclonic · United States2Active, not recruitingMar 31, 202960
NCT04442295Epilepsies, Myoclonic · United States2CompletedNov 14, 202362

How it is read

Names in the registry

  • “zorevunersen”, 1 entry
  • “zorevunersen (STK-001)”, 1 entry
  • “STK-001 - Single Ascending Doses”, 1 entry
  • “STK-001 - Multiple Ascending Doses”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.